GEMCITABINE : A NUCLEOSIDE ANALOG IN CANCER TREATMENT

Gemcitabine is a nucleoside analog widely used in chemotherapy for various cancers, including pancreatic, breast, ovarian, and non-small cell lung cancer. Its mechanism of action involves inhibiting DNA synthesis, thereby slowing or stopping cancer cell growth. Gemcitabine is administered intravenously and is often used in combination with other medications to enhance its efficacy. Common side effects include nausea, fatigue, and neutropenia, which are manageable with appropriate medical care. Monitoring of blood counts and liver function is essential during treatment to minimize adverse effects. Gemcitabine’s role in cancer treatment has been established through numerous clinical trials, demonstrating its effectiveness in improving survival rates and quality of life for patients. Ongoing research explores its potential use in combination with other therapies, such as targeted therapy and immunotherapy, to further enhance its efficacy. As a well-tolerated and effective chemotherapy agent, gemcitabine remains a valuable treatment option for patients with various types of cancer KEYWORDS : Gemcitabine, nucleoside analog, cancer treatment, chemotherapy, pancreatic cancer, breast cancer, ovarian cancer, non-small cell lung cancer, DNA synthesis inhibition